Leadership & Organization

The NOVA institute for Medical Systems Biology (NIMSB) is a centre of excellence in biomedical research whose discoveries and innovation projects will contribute to improve the quality of life for patients, reduce mortality, promote sustainable societal development, and enhancing Portugal’s competitive position in Europe and worldwide. The NIMSB project had its genesis in Health Platform and was developed with the objective of stimulating excellence research in areas associated with precision medicine, promoting interdisciplinary collaboration, concentration of resources and competencies, and internationalization.

NIMSB is a Strategic Platform of NOVA, as defined in the University’s Statutes, in Article 35, crossing the competencies mentioned above.

MEET THE BOARD OF DIRECTORS

The Board of Directors (BoD) is the body responsible for the executive direction of NIMSB, ensuring its scientific, operational, financial, and administrative management.

The members of the BoD are:
The Scientific Director, who presides the board and has the casting vote, the Financial and Administrative Director and the Vice-Directors for Impact & Finantial Sustainability and for Research.

BOARD OF DIRECTORS

António Jacinto

Scientific Director

Alda Castro

Finance and Administrative Director

Sofia Miguel

Vice-Director

Cláudia Nunes

Vice-Director

Ana Pombo

MDC representative

MEET THE COORDINATION COMMITTEE

This committee is the support body to the Supervisory Board that ensures the articulation between NIMSB and NOVA’s schools. The committee is constituted by the vice-rector for Research and Innovation, who presides, a member appointed by the Rector, who assists and by one representative of each school participating in the platform, appointed by the respective Dean.

These members are mainly responsible for the monitoring of NIMSB implementation and performance and NIMSB activities carried out in collaboration with NOVA’s schools. They also issue opinions and recommendations to the Supervisory Board whenever requested or whenever deemed necessary.

NIMSB-NOVA COORDINATION COMMITTEE

Cecília Roque

President

Emília Monteiro

Representative appointed by the Rector

Eurico Cabrita

FCT NOVA

João Conde

NMS

Vera Lúcia Raposo

NOVA Law

Miguel Viveiros

IHMT NOVA

Leonardo Vannechi

NOVA IMS

Raquel Sá-Leão

ITQB NOVA

Susana Viegas

ENSP

SUPERVISORY BOARD

SUPERVISORY BOARD

MEET THE SUPERVISORY BOARD

The Supervisory Board (SB) is the strategic decision-making and supervisory body of NIMSB. This Board is composed of five members, three of whom are appointed by the Rector, heard the Coordination Committee, and two members appointed by the Director of the MDC. The SB is chaired by one of its members, appointed by the Rector.

The Supervisory Board is responsible for monitoring the legality, effectiveness, and economic efficiency of the management of all the activities of NIMSB and can request at any time reports from the Board of Directors. It determines which decisions of the Board of Directors require the prior approval of the Supervisory Board and may issue instructions about important matters involving political aspects of the research and financial affairs of the institute.

 

Cecília Roque

President

Isabel Fragata

NOVA

Emília Monteiro

Representative appointed by the Rector

Young-Ae Lee

MDC

Nikolaus Rajewsky

MDC

SCIENTIFIC ADVISORY BOARD

MEET THE SCIENTIFIC ADVISORY BOARD

The Scientific Advisory Board (SAB) is an advisory body for internal evaluation and counseling on strategic, scientific orientation, and maximizing societal impact.

It is composed of members external to NOVA, including international experts with recognized scientific competence in the NIMSB’s field of activity and representatives of partners and stakeholders, namely, NOVA, MDC, regional and national authorities, patient associations, medical organizations, hospitals, and sector companies. The composition and functioning of the Board are ruled by the funding agreement of NIMSB between the European Research Executive Agency of the European Commission and NOVA and by the consortium agreement between NOVA and MDC.

More information coming soon…